Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion type Assertion NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_head.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion description "[The clinical relevance of these findings is strongly supported since TCD-717 has recently entered Phase I clinical trials against solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_provenance.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion evidence source_evidence_literature NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_provenance.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion SIO_000772 23762272 NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_provenance.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion wasDerivedFrom befree-20150227 NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_provenance.
- NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_assertion wasGeneratedBy ECO_0000203 NP313808.RAEObz-z2wB6bxs20JavPEDc9-32bnd8ne0oPd3JI3EeI130_provenance.